Apple: Still Early For The Holy Grail
Apple continues working on turning the Apple Watch into a medical device. The tech giant has made progress on a glucose monitoring system with the signs the concept works, but the company needs to scale the product into a wearable form factor. The stock is already priced for a Holy Grail new product, while investors should buy the stock when a new medical device is a bonus for a cheap stock. Apple shouldn't already trade at 25x FY23 EPS targets. The holy grail of the Apple ( NASDAQ: AAPL ) Watch is turning the product into a medical device. The tech company has a promising new use for the watch, but the market has already hyped the entry of the company into the blood glucose monitoring market. My investment thesis remains ultra Bearish on the stock until investors can purchase the stock with upside potential from such new products, instead of the current scenario where Apples falls unless the company releases new hit products. Read the full article ...